BG
LMAT icon

Bahl & Gaynor’s LeMaitre Vascular LMAT Stock Holding History

Bahl & Gaynor’s Portfolio LMAT Stock Details LMAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.6M Sell
124,528
-265
-0.2% -$25.3K 0.07% 129
2025
Q4 		$10.1M Sell
124,793
-188
-0.2% -$16.2K 0.05% 142
2025
Q3 		$10.9M Buy
124,981
+2,066
+2% +$184K 0.05% 140
2025
Q2 		$10.2M Buy
122,915
+969
+0.8% +$81K 0.05% 139
2025
Q1 		$10.2M Sell
121,946
-301
-0.2% -$28K 0.05% 139
2024
Q4 		$11.3M Sell
122,247
-7,081
-5% -$681K 0.06% 131
2024
Q3 		$12M Buy
129,328
+856
+0.7% +$74.2K 0.06% 128
2024
Q2 		$10.6M Buy
128,472
+2,595
+2% +$191K 0.06% 131
2024
Q1 		$8.35M Buy
125,877
+278
+0.2% +$17.2K 0.05% 141
2023
Q4 		$7.13M Buy
125,599
+5,207
+4% +$273K 0.04% 144
2023
Q3 		$6.56M Sell
120,392
-5,815
-5% -$345K 0.04% 141
2023
Q2 		$8.49M Sell
126,207
-21,851
-15% -$1.33M 0.05% 133
2023
Q1 		$7.62M Sell
148,058
-29,950
-17% -$1.45M 0.04% 134
2022
Q4 		$8.19M Sell
178,008
-2,103
-1% -$98.5K 0.05% 132
2022
Q3 		$9.13M Sell
180,111
-39,117
-18% -$1.95M 0.06% 120
2022
Q2 		$9.99M Buy
219,228
+3,066
+1% +$137K 0.07% 117
2022
Q1 		$10M Sell
216,162
-4,074
-2% -$182K 0.07% 111
2021
Q4 		$11.1M Buy
220,236
+13,294
+6% +$687K 0.06% 120
2021
Q3 		$11M Buy
206,942
+1,114
+0.5% +$62.7K 0.07% 108
2021
Q2 		$12.6M Sell
205,828
-8,546
-4% -$454K 0.08% 102
2021
Q1 		$10.5M Buy
214,374
+15,218
+8% +$713K 0.07% 111
2020
Q4 		$8.06M Buy
199,156
+2,775
+1% +$99.2K 0.05% 120
2020
Q3 		$6.39M Buy
196,381
+23,159
+13% +$695K 0.05% 125
2020
Q2 		$4.57M Sell
173,222
-26,445
-13% -$691K 0.03% 147
2020
Q1 		$4.97M Sell
199,667
-30,340
-13% -$937K 0.04% 132
2019
Q4 		$8.27M Sell
230,007
-1,821
-0.8% -$62.8K 0.06% 118
2019
Q3 		$7.92M Buy
231,828
+487
+0.2% +$15.6K 0.06% 116
2019
Q2 		$6.47M Sell
231,341
-8,226
-3% -$229K 0.05% 122
2019
Q1 		$7.43M Buy
239,567
+30,247
+14% +$807K 0.07% 98
2018
Q4 		$4.95M Buy
209,320
+31,301
+18% +$855K 0.05% 109
2018
Q3 		$6.9M Buy
178,019
+39,817
+29% +$1.43M 0.09% 101
2018
Q2 		$4.63M Buy
138,202
+61,946
+81% +$2.2M 0.05% 130
2018
Q1 		$2.76M Buy
76,256
+12,431
+19% +$431K 0.03% 174
2017
Q4 		$2.03M Buy
63,825
+820
+1% +$28.1K 0.02% 213
2017
Q3 		$2.36M Buy
63,005
+9,980
+19% +$340K 0.03% 182
2017
Q2 		$1.66M Buy
53,025
+4,440
+9% +$128K 0.02% 208
2017
Q1 		$1.2M Buy
48,585
+5,320
+12% +$125K 0.01% 233
2016
Q4 		$1.1M Buy
43,265
+6,535
+18% +$145K 0.01% 238
2016
Q3 		$728K Buy
36,730
+3,350
+10% +$58.5K 0.01% 276
2016
Q2 		$476K Buy
33,380
+2,380
+8% +$36.4K 0.01% 319
2016
Q1 		$481K Buy
+31,000
New +$444K 0.01% 315

Other funds holding LMAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bahl & Gaynor's LMAT Position: Q1 2026 in Review

Bahl & Gaynor reduced its LeMaitre Vascular (LMAT) stake by 0.21% in Q1 2026, selling an estimated $25.3K and leaving 124,528 shares worth $13.6M. The position accounts for 0.07% of the portfolio, ranked #129.

Bahl & Gaynor first reported a position in LMAT in Q1 2016 and has held it in 41 quarters since. 339 funds tracked by Wall St. Rank hold LMAT as of Q1 2026.

  • Bahl & Gaynor held 124,528 shares of LeMaitre Vascular worth $13.6M as of Q1 2026.
  • Bahl & Gaynor sold 265 LeMaitre Vascular shares in Q1 2026, an estimated $25.3K.
  • LeMaitre Vascular made up 0.07% of Bahl & Gaynor's portfolio in Q1 2026, its #129 holding.
  • Bahl & Gaynor first reported a position in LeMaitre Vascular in Q1 2016 and has held it in 41 quarters since.
  • 339 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q1 2026.

Based on Bahl & Gaynor's 13F filing for Q1 2026, filed 7 May 2026.